November 2023
Upcoming RSV Webinar: “RSV Travels by Airplane”
During the 14th webinar of ReSViNET’s RSV Webinar Series, Prof Philippe Lemey, will share his insights on RSV Travels by Airplane. He is the senior editor of the second edition of the Phylogenetic Handbook and a two-time ERC grant awardee. Philippe is now a full Professor at the Rega Institute, KU Leuven, where he studies the evolutionary processes that shape viral genetic diversity, spanning large-scale epidemic processes as well as small-scale transmission histories and within-host evolutionary processes.
Date: Wednesday, 29th November 2023
Time: 16:00 – 17:00 CEST
September 2023
Registration for RSVVW’24 is open!
On 13-16 February, 2024, we will host our 8th conference RSVVW’24 – A Global Conference on Novel RSV Preventive and Therapeutic Interventions. We are looking forward to welcoming you at our in-person conference in Mumbai, India.
Find more information about RSVVW’24 on the conference homepage!
Webinar Recording Available: “RSV and Asthma”
Our latest ReSViNET Webinar was held on the 6th of September with Prof Tina Hartert, MD, MPH, as our guest speaker. She shared her insights on RSV in relationship to asthma. Her study of almost two thousand children has identified that delay in early life respiratory syncytial virus (RSV) decreases the risk of developing childhood asthma. These findings underscore the role of RSV in both acute and chronic respiratory disease and pave the way for asthma prevention efforts.
August 2023
Paper of the Month: August 2023
Respiratory syncytial virus infection and novel interventions
Authors: Annefleur C. Langedijk & Louis J. Bont
The large global burden of respiratory syncytial virus (RSV) respiratory
tract infections in young children and older adults has gained
increased recognition in recent years. Recent discoveries regarding
the neutralization-specifc viral epitopes of the pre-fusion RSV
glycoprotein have led to a shift from empirical to structure-based design
of RSV therapeutics, and controlled human infection model studies
have provided early-stage proof of concept for novel RSV monoclonal
antibodies, vaccines and antiviral drugs.
Upcoming RSV Webinar: “RSV and Asthma”
During the 13th webinar of ReSViNET’s RSV Webinar Series, Prof Tina Hartert, MD, MPH, will share her insights on RSV in relationship to asthma. Her study of almost two thousand children has identified that delay in early life respiratory syncytial virus (RSV) decreases the risk of developing childhood asthma. These findings underscore the role of RSV in both acute and chronic respiratory disease and pave the way for asthma prevention efforts.
July 2023
BANGLADESH’S DYNAMIC DUO BATTLE GLOBAL HEALTH INEQUITY
A father-daughter team is working to reduce child mortality in Bangladesh.
As a little girl growing up in Bangladesh, Senjuti Saha remembers how dinner conversations in her family often focused on bacteria, viruses, and infectious diseases.
Those topics might strike many people as a little gross at mealtime, but in the Saha family that’s what happened when her father, Dr. Samir Saha, brought his work home. A professor of microbiology, Samir used family dinner to practice his scientific lectures or share what he was learning about Bangladesh’s health challenges.
Paper of the Month: July 2023
Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study
Authors: Tina Hartert et al.
Early-life severe respiratory syncytial virus (RSV) infection has been associated with the onset of childhood wheezing illnesses. However, the relationship between RSV infection during infancy and the development of childhood asthma is unclear. We aimed to assess the association between RSV infection during infancy and childhood asthma.
June 2023
Travel Grant Application is OPEN!
We are delighted to announce that on 13-16 February 2024, the ReSViNET Foundation will host its 8th conference RSVVW’24 – A Global Conference on Novel RSV Preventive and Therapeutic Interventions.
A travel grant offers a great opportunity for young researchers and participants from lower- and middle income countries to attend RSVVW’24 in Mumbai, India.
Deadline: July 9th
Paper of the Month: June 2023
Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine Elke Jordan et al.
Respiratory syncytial virus (RSV) causes significant disease burden in older adults. MVA-BN-RSV is a novel poxvirus-vectored vaccine encoding internal and external RSV proteins.
RSVVW’24 travel grant application has opened!
We are delighted to announce that on 13-16 February 2024, the ReSViNET Foundation will host its 8th conference RSVVW’24 – A Global Conference on Novel RSV Preventive and Therapeutic Interventions.
A travel grant offers a great opportunity for young researchers and participants from lower- and middle income countries to attend RSVVW’24 in Mumbai, India.
All travel grant recipients are required to submit an abstract and present a poster, so you will be sharing your work with experts in the field.
May 2023
Paper of the Month: May 2023
Prioritising respiratory syncytial virus prevention inlow-income and middle-income countries
Xavier Carbonell-Estrany et al.
RSV disease burden in children below 5 in 72 GAVI eligible countries.
Image from: Li, X. et al. BMC Med 18, 82 (2020). https://doi.org/10.1186/s12916-020-01537-6
Over the past few years, the advent of several preventive interventions finally provides opportunities to address the burden of respiratory syncytial virus disease. However, in the past, new vaccines to prevent important respiratory illnesses were author…
RSVVW’24 Conference Mumbai
We are delighted to announce that on 14-16 February 2024, the ReSViNET Foundation will host its 8th conference RSVVW’24 – A Global Conference on Novel RSV Preventive and Therapeutic Interventions. After a successful conference in 2022, held in Lisbon, Portugal, we are looking forward to welcoming you at our next in-person conference in Mumbai, India.
April 2023
Paper of the Month: April 2023
Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies have shown that the nirsevimab binding site is highly conserved. However, investigations of the geotemporal evolution of potential escape variants in recent (ie, 2015–2021)…
This is how you can help: participate in our survey and spread the word!
Help us understand parents’ awareness of RSV, and their needs when vaccinating their child. It will only take 2-3 minutes of your time.
RSV Dashboard
We are proud to announce we have developed the first-ever global RSV surveillance dashboard and it is now live!
ReSViNET Foundation, in collaboration with AstraZeneca, is supporting healthcare decisions by providing transparency and accessibility to shared global RSV surveillance data. The dashboard will help simplify tracking changes in RSV seasonality globally. This will include at least 20 countries that are representative of different geographic regions from both hemispheres.
